Emilien Billon, Cécile Dalban, Stephane Oudard, Christine Chevreau, Brigitte Laguerre, Philippe Barthélémy, Delphine Borchiellini, Lionnel Geoffrois, Sylvie Negrier, Florence Joly, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Frederic Rolland, Frank Priou, Hakim Mahammedi, Florence Tantot, Bernard Escudier, Sylvie Chabaud, Laurence Albiges, Gwenaelle Gravis
BACKGROUND: Glandular metastases (GMs; adrenal gland, pancreas, thyroid, ovary, breast, or prostate) are rare in metastatic clear cell renal cell carcinoma (mccRCC). Previous studies have indicated that GM patients treated with antiangiogenic therapy experience significantly longer overall survival (OS). OBJECTIVES: To assess outcomes for mccRCC with or without GMs treated with nivolumab. DESIGN, SETTING, AND PARTICIPANTS: The GETUG-AFU-26 NIVOREN phase 2 trial evaluated the activity and safety of nivolumab in patients with mccRCC who experienced failure of antiangiogenic therapies (NCT03013335)...
October 7, 2023: European Urology Oncology